Streetbeat News

MYNZ

Mainz Biomed B.V.

Industry

Medical - Diagnostics & Research

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

Open

4.12

Mkt cap

9.5M

Volume

68K

High

4.31

P/E Ratio

-0.10

52-wk high

8.20

Low

4.06

Div yield

N/A

52-wk low

0.18

Mainz Biomed and Liquid Biosciences have discovered mRNA biomarkers for detecting pancreatic cancer with high sensitivity and specificity. Mainz Biomed has entered an exclusive licensing agreement for these biomarkers and will continue developing an AI-based algorithm for detection.

Portfolio Pulse from

March 13, 2025 | 12:15 pm

Mainz Biomed N.V. is expanding its operations into Switzerland by establishing a new labor team. This strategic move is part of the company's growth plan.

Portfolio Pulse from

February 20, 2025 | 1:15 pm

Mainz Biomed and GANZIMMUN have launched an enhanced version of ColoAlert, a colorectal cancer screening test, ahead of Colorectal Cancer Awareness Month. This development aims to improve early detection and prevention of colorectal cancer.

Portfolio Pulse from

February 11, 2025 | 1:15 pm

Mainz Biomed has launched a U.S. clinical study, eAArly DETECT 2, to evaluate its next-generation colorectal cancer test on advanced adenomas in a large patient population. The study aims to validate previous results and is expected to complete enrollment in the second half of 2025.

Portfolio Pulse from

January 21, 2025 | 1:15 pm

Mainz Biomed has entered into an agreement with Quest Diagnostics to provide clinical trials laboratory services for a colorectal cancer screening test. This partnership aims to enhance the development and potential market reach of Mainz Biomed's screening test.

Portfolio Pulse from

December 19, 2024 | 1:15 pm

Mainz Biomed N.V. has successfully closed an $8.0 million follow-on offering, which could provide the company with additional capital for its operations and growth initiatives.

Portfolio Pulse from

December 16, 2024 | 10:15 pm

Mainz Biomed N.V. (MYNZ) has announced a 1-for-40 reverse stock split, effective December 3, following its collaboration with Thermo Fisher Scientific.

Portfolio Pulse from

December 03, 2024 | 8:00 pm

Mainz Biomed N.V. has announced a stock split, which could impact the trading dynamics of its shares.

Portfolio Pulse from

November 29, 2024 | 2:00 pm

Mainz Biomed reported a revenue of $0.52 million for the first half of 2024, marking a 4% increase year-over-year. However, the company also reported an EPS loss of $(0.49).

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 12:06 pm

The article highlights significant intraday movements in healthcare stocks, with NewGenIvf Group, Gritstone Bio, and Vicarious Surgical among the top gainers, while Seelos Therapeutics and Mainz Biomed are notable losers.

Portfolio Pulse from Benzinga Insights

October 15, 2024 | 4:32 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.